SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Mäenpää J)
 

Search: WFRF:(Mäenpää J) > SCOTROC 2B :

  • Clamp, A. R. (author)

SCOTROC 2B : feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • 2005-12-13
  • Springer Science and Business Media LLC,2006
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-11114
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-11114URI
  • https://doi.org/10.1038/sj.bjc.6602910DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Mäenpää, J. (author)
  • Cruickshank, D. (author)
  • Ledermann, J. (author)
  • Wilkinson, P. M. (author)
  • Welch, R. (author)
  • Chan, S. (author)
  • Vasey, P. (author)
  • Sorbe, BengtÖrebro universitet,Institutionen för klinisk medicin(Swepub:oru)bse (author)
  • Hindley, A. (author)
  • Jayson, G. C. (author)
  • Örebro universitetInstitutionen för klinisk medicin (creator_code:org_t)

Related titles

  • In:British Journal of Cancer: Springer Science and Business Media LLC94:1, s. 55-610007-09201532-1827

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view